我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

microRNA在肺动脉高压形成中的作用

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第4期
页码:
494-498
栏目:
综述
出版日期:
2013-07-25

文章信息/Info

Title:
Roles of microRNA in pulmonary arterial hypertension
作者:
赵施皓1; 杨智伟1; 郑煦暘1; 冯 娜2; 李 娟2; 裴建明2
(第四军医大学：1.口腔医学系3队，2.基础部生理学教研室，陕西 西安 710032)
Author(s):
ZHAO Shi-hao1;  YANG Zhi-wei1;  ZHENG Xu-yang1;  FENG Na2;  LI Juan2;  PEI Jian-ming2
(1.Team 3, Brigade of Stomatology, 2.Department of Physiology, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
肺动脉高压; 微小RNA; 内皮细胞; 血管平滑肌细胞
Keywords:
pulmonary arterial hypertension;  microRNA;  endothelial cells;  vascular smooth muscle cells
分类号:
R543.2
DOI:
-
文献标识码:
A
摘要:
微小RNA（microRNA）是真核细胞内源性表达、高度保守、长度约为22个核苷酸的非编码RNA，可以调控基因的表达，与众多疾病的发生发展有关。近期研究发现，多种microRNAs表达失调在肺动脉高压（pulmonary arterial hypertension，PAH）及多种心血管疾病的发展中起重要作用，其成为新的分子生物学标志并有广泛的治疗应用前景。本文就microRNA在PAH中的作用作一综述。
Abstract:
MicroRNAs are endogenously expressed and highly conserved non-coding RNAs which regulate gene expressions in eukaryons. Recent studies have found that the dysregulation of some microRNAs plays an important role in pulmonary arterial hypertension (PAH) and some other cardiovascular diseases. MicroRNAs thus become novel biomarkers of these diseases and show potentials of clinical applications. This review focuses on the roles of microRNAs in PAH.

参考文献/References

[1]苗 裔，臧伟进.microRNA-21及相关技术在心血管疾病中的研究进展[J].心脏杂志,2011,23(2):255-259.

[2]陈 婷,王长谦.MicroRNA在心血管疾病中作用的研究进展[J].心脏杂志,2009,21(5):730-734.

[3]Weber M,Baker MB,Moore JP,et al.MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activity[J].Biochem Biophys Res Commun,2010,393(4):643-648.

[4]Sarkar J,Gou D,Turaka P,et al.MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration[J].Am J Physiol Lung Cell Mol Physiol,2010, 299(6):861-871.

[5]Davis BN,Hilyard AC,Lagna G,et al.SMAD proteins control DROSHA-mediated microRNA maturation[J].Nature,2008,454(7200):56-61.

[6]Parikh VN,Jin RC,Rabello S,et al.MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach[J].Circulation,2012,125(12):1520-1532.

[7]Yang S,Banerjee S,Freitas Ad,et al.MiR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling[J].Am J Physiol Lung Cell Mol Physiol,2012,302(6):521-529.

[8]Yan L,Hao H,Elton TS,et al.Intronic microRNA suppresses endothelial nitric oxide synthase expression and endothelial cell proliferation via inhibition of STAT3 signaling[J].Mol Cell Biochem,2011,357(1-2):9-19.

[9]Courboulin A,Paulin R,Giguère NJ,et al.Role for miR-204 in human pulmonary arterial[J].J Exp Med,2011,208(3): 535-548.

[10]Brock M,Trenkmann M,Gay RE,et al.Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway[J].Circ Res,2009,104(10):184-1191.

[11]Bonnet S,Rochefort G,Sutendra G,et al.The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted[J].Proc Natl Acad Sci U S A,2007,104(27):11418-11423.

[12]Guo L,Qiu Z,Wei L,et al.The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-α1C[J].Hypertension,2012,59(5): 1006-1013.

[13]Cheng Y,Liu X,Yang J,et al.MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation[J].Circ Res,2009,105(2):158-166.

[14]Cordes KR,Sheehy NT,White MP,et al.miR-145 and miR-143 regulate smooth muscle cell fate and plasticity[J]. Nature,2009,460(7256):705-710.

[15]Boettger T,Beetz N,Kostin S,et al.Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the miR143/145 gene cluster[J].J Clin Invest,2009,119(9):2634-2647.

[16]Elia L,Quintavalle M,Zhang J,et al.The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease[J].Cell Death Differ,2009,16(12):1590-1598.

[17]Xin M,Small EM,Sutherland LB,et al.MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury[J].Genes Dev,2009,23(18):2166-2178.

[18]Caruso P,Dempsie Y,Stevens HC,et al.A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples[J].Circ Res,2012,111(3):290-300.

[19]Bockmeyer CL,Maegel L,Janciauskiene S,et al.Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression[J].J Heart Lung Transplant,2012,31(7):764-772.

[20]Davis-Dusenbery BN,Chan MC,Reno KE,et al.down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4［J］. J Biol Chem, 2011, 286(32):28097-28110.

[21]Pullamsetti SS, Doebele C, Fischer A, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension［J］. Am J Respir Crit Care Med, 2012, 185(4):409-419.

[22]Dentelli P,Rosso A,Orso F,et al.microRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression[J].Arterioscler Thromb Vasc Biol,2010,30(8):1562-1568.

备注/Memo

备注/Memo:
收稿日期：2012-11-21.基金项目：国家自然科学基金项目资助(30900535，30971060， 31100827，81270402，31200875)；陕西省攻关课题项目资助（2010K01195）和陕西省自然科学基金 项目资助(2011JM4001) 通讯作者：李娟，讲师，主要从事κ阿片受体介导心肺循环保护的研究 Email：lijuan2162008@163.com 作者简介：赵施皓，本科生 Email：765595720@qq.com 共同第一作者：杨智伟，本科生 Email：502278
更新日期/Last Update: 2013-07-29